Delpharm Enters into Exclusive Negotiations with Famar
Delpharm and Famar, two of the European leaders in contract manufacturing and development of medicines...
Five manufacturing sites in France, Canada and the Netherlands, which previously belonged to the Farmar Group, have been acquired by Delpharm, the two companies have announced.
The transaction signed 18 November covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands.
This group of five sites represents a turnover of €250m and 1,300 employees.
Patrick Puy, President of Famar said: “This acquisition by Delpharm, a reputable CDMO, represents a great opportunity for the 1,300 Famar colleagues and will allow the sites to foresee a fruitful and sustainable future.”
Sébastien Aguettant, President of Delpharm said: “With a headcount of 4,700 people working on 17 manufacturing sites, Delpharm is reaching a new level and is now part of the top 5 CDMOs worldwide.”
Delpharm and the Famar Group wish to thank all the stakeholders who worked hard to make this deal happen, especially the French authorities, for their positive involvement.
Delpharm and Famar, two of the European leaders in contract manufacturing and development of medicines...
Delpharm offers its knowledge and experience to manufacture licensed products, generics, over-the-counter (OTC) drugs, dietary...
Delpharm provides formulation, analytical services, clinical batches, regulatory affairs and life cycle management solutions through...
Delpharm is pleased to announce its participation at Vitafoods Europe. The company is a European...